Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cenegermin - Dompe Farmaceutici

Drug Profile

Cenegermin - Dompe Farmaceutici

Alternative Names: Cenegermin-bkbj; Nerve growth factor - Anabasis/Dompe; Oxervate; rhNGF; Sentinel

Latest Information Update: 14 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anabasis Pharma
  • Developer Dompe Farmaceutici; Ospedale San Raffaele
  • Class Eye disorder therapies; Nerve growth factors; Neuroprotectants; Proteins
  • Mechanism of Action Nerve growth factor receptor agonists; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratitis; Retinitis pigmentosa
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Keratitis
  • Phase II Dry eyes; Glaucoma; Retinitis pigmentosa

Most Recent Events

  • 10 Jun 2019 Dompe Farmaceutici initiates a phase-II trial for Dry eyes in USA (NCT03982368)
  • 14 Mar 2019 Dompé Farmaceutici receives industry innovation award from the National Organization of Rare Disorders (NORD) for the development of cenegermin in Keratitis
  • 03 Jan 2019 Launched for Keratitis (In adolescents, In children, In the elderly, In adults) in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top